1240 Increased Mucosal Innate Immune Activation in Hereditary Alpha Trytpasemia Subjects Is Predictive of Clinical Response to Tofacitanib Therapy
Glover S, Davis E, Shirley J, Konnikova L. 1240 Increased Mucosal Innate Immune Activation in Hereditary Alpha Trytpasemia Subjects Is Predictive of Clinical Response to Tofacitanib Therapy. The American Journal Of Gastroenterology 2019, 114: s691-s692. DOI: 10.14309/01.ajg.0000594488.99132.5d.Peer-Reviewed Original ResearchInnate immune activationIntestinal epithelial cellsImmune activationClinical responsePyroptosis levelsAbdominal painGI symptomsClonal mast cell diseaseLevels of pyroptosisSmall bowel biopsyMemory T cellsMcg/LTime of biopsyElevated serum tryptaseMast cell diseaseType of therapyJAK-STAT inhibitorBowel biopsyElevated tryptaseIEC pyroptosisAdalimumab therapyClinical symptomsHistologic evidenceMC activationTryptase levels